Trevi Therapeutics, Inc. stock is down -22.92% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 December’s closed higher than November.
Trevi Therapeutics is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.